Evidence map›Paper›PMID 27707967›Full record

ArticleThe Journal of neuroscience : the official journal of the Society for Neuroscience2016

Neuronal Dystroglycan Is Necessary for Formation and Maintenance of Functional CCK-Positive Basket Cell Terminals on Pyramidal Cells.

Simon Früh, Jennifer Romanos, Patrizia Panzanelli, Daniela Bürgisser, Shiva K Tyagarajan, Kevin P Campbell, Mirko Santello, Jean-Marc Fritschy

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of neuroscience : the official journal of the Society for Neuroscience, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed
5.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 92 citations in OpenAlex.

  1. Article
  2. Neuroligin-2-Dependent Adhesion Defines a Molecular Checkpoint for Inhibitory Synaptic Plasticity.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2026
    Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Alpha-neurexins in health and disease.Frontiers in molecular neuroscience · 2025
    Review
  10. Multi-level therapeutic actions of cannabidiol in ketamine-induced schizophrenia psychopathology in male rats.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Abnormal Expression of Synaptic and Extrasynaptic GABAInternational journal of molecular sciences · 2022
    Article
  18. Article
  19. Integrins Bidirectionally Regulate the Efficacy of Inhibitory Synaptic Transmission and Control GABAergic Plasticity.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2022
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 3 countries.

Simon FrühInstitute of Pharmacology and Toxicology, University of Zurich, 8057 Zurich, Switzerland, Neuroscience Center Zurich, University of Zurich and ETH Zurich, 8057 Zurich, Switzerland.
Jennifer RomanosInstitute of Pharmacology and Toxicology, University of Zurich, 8057 Zurich, Switzerland, Neuroscience Center Zurich, University of Zurich and ETH Zurich, 8057 Zurich, Switzerland.
Patrizia PanzanelliDepartment of Neuroscience Rita Levi Montalcini, University of Turin, 10124 Turin, Italy.
Daniela BürgisserETH Zurich, 8092 Zurich, Switzerland.ORCID 0000-0001-9709-0150
Shiva K TyagarajanInstitute of Pharmacology and Toxicology, University of Zurich, 8057 Zurich, Switzerland, Neuroscience Center Zurich, University of Zurich and ETH Zurich, 8057 Zurich, Switzerland.ORCID 0000-0003-0074-1805
Kevin P CampbellHoward Hughes Medical Institute, Department of Molecular Physiology and Biophysics, Department of Neurology, University of Iowa Roy J. and Lucille A. Carver College of Medicine, Iowa City, Iowa 52242, and.ORCID 0000-0003-2066-5889
Mirko SantelloInstitute of Pharmacology and Toxicology, University of Zurich, 8057 Zurich, Switzerland, Neuroscience Center Zurich, University of Zurich and ETH Zurich, 8057 Zurich, Switzerland.ORCID 0000-0002-7709-4127
Jean-Marc FritschyInstitute of Pharmacology and Toxicology, University of Zurich, 8057 Zurich, Switzerland, Neuroscience Center Zurich, University of Zurich and ETH Zurich, 8057 Zurich, Switzerland fritschy@pharma.uzh.ch.ORCID 0000-0002-8552-3702
University of Zurich · CHETH Zurich · CHUniversity of Iowa · USUniversity of Turin · IT

Funding

Therapeutic Potential of ESC-Derived Myogenic PrecursorsU54NS053672 · NINDS · UNIVERSITY OF IOWA · PI CAMPBELL, KEVIN P. · 2005 to 2019
$22.0M
NINDS NIH HHS U54 NS053672
6 · The paper itself

Abstract

Distinct types of GABAergic interneurons target different subcellular domains of pyramidal cells, thereby shaping pyramidal cell activity patterns. Whether the presynaptic heterogeneity of GABAergic innervation is mirrored by specific postsynaptic factors is largely unexplored. Here we show that dystroglycan, a protein responsible for the majority of congenital muscular dystrophies when dysfunctional, has a function at postsynaptic sites restricted to a subset of GABAergic interneurons. Conditional deletion of Dag1, encoding dystroglycan, in pyramidal cells caused loss of CCK-positive basket cell terminals in hippocampus and neocortex. PV-positive basket cell terminals were unaffected in mutant mice, demonstrating interneuron subtype-specific function of dystroglycan. Loss of dystroglycan in pyramidal cells had little influence on clustering of other GABAergic postsynaptic proteins and of glutamatergic synaptic proteins. CCK-positive terminals were not established at P21 in the absence of dystroglycan and were markedly reduced when dystroglycan was ablated in adult mice, suggesting a role for dystroglycan in both formation and maintenance of CCK-positive terminals. The necessity of neuronal dystroglycan for functional innervation by CCK-positive basket cell axon terminals was confirmed by reduced frequency of inhibitory events in pyramidal cells of dystroglycan-deficient mice and further corroborated by the inefficiency of carbachol to increase IPSC frequency in these cells. Finally, neurexin binding seems dispensable for dystroglycan function because knock-in mice expressing binding-deficient T190M dystroglycan displayed normal CCK-positive terminals. Together, we describe a novel function of dystroglycan in interneuron subtype-specific trans-synaptic signaling, revealing correlation of presynaptic and postsynaptic molecular diversity. SIGNIFICANCE STATEMENT: Dystroglycan, an extracellular and transmembrane protein of the dystrophin-glycoprotein complex, is at the center of molecular studies of muscular dystrophies. Although its synaptic distribution in cortical brain regions is long established, function of dystroglycan in the synapse remained obscure. Using mice that selectively lack neuronal dystroglycan, we provide evidence that a subset of GABAergic interneurons requires dystroglycan for formation and maintenance of axonal terminals on pyramidal cells. As such, dystroglycan is the first postsynaptic GABAergic protein for which an interneuron terminal-specific function could be shown. Our findings also offer a new perspective on the mechanisms that lead to intellectual disability in muscular dystrophies without associated brain malformations.

Indexed as

AnimalsCalcium-Binding ProteinsCarbacholCholecystokininDystroglycansExcitatory Postsynaptic PotentialsFemalegamma-Aminobutyric AcidGene Knock-In TechniquesInterneuronsMaleMiceMice, Inbred C57BLMice, KnockoutMuscarinic AgonistsNeural Cell Adhesion MoleculesCalcium-Binding ProteinsCarbacholCholecystokininDystroglycansgamma-Aminobutyric AcidMuscarinic AgonistsNeural Cell Adhesion MoleculesNrxn1 protein, mousecholecystokinindystroglycanopathydystrophin-glycoprotein complexGABAinterneuronsperisomatic

Identifiers

PMID27707967
PMCPMC6705590
OpenAlexW2528855935

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.